Last updated on March 2016

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven PhaseIII study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease insubjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease


Brief description of study

A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven PhaseIII study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease insubjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

Detailed Study Description

Demonstrate whether finerenone is superior to placebo in delaying the progression of kidney disease. Randomized at 1:1 ratio. Subjects will take one pill once a day.

Clinical Study Identifier: TX143053

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.